Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Emel Aygören-Pürsün, MD
University Hospital Frankfurt - Goethe University, Frankfurt, Germany
Principal Investigator - Marc Riedl, MD
UC San Diego, La Jolla, California, United States
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Study Site
Vienna, Austria
- Study Site
Sofia, Bulgaria
- Study Site
Ottawa, Ontario, Canada
- Study Site
Montreal, Quebec, Canada
- Study Site
Berlin, Germany
- Study Site
Frankfurt, Germany
- Study Site
Dublin, Ireland
- Study Site
Padua, PD, Italy
- Study Site
Milan, Italy
- Study Site
Palermo, Italy
- Study Site
Krakow, Poland
- Study Site
Brighton, England, United Kingdom
- Study Site
Bristol, England, United Kingdom
- Study Site
Cambridge, England, United Kingdom
- Study Site
London, England, United Kingdom
- Study Site
Southampton, England, United Kingdom
- Study Site
Birmingham, Alabama, United States
- Study Site
Paradise Valley, Arizona, United States
- Study Site
St Louis, Missouri, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Apr 2022
- Primary completion
- 30 Jun 2025
- Completion
- 30 Jun 2025
- Last update posted
- 30 Jul 2025
- Registered enrollment
- 34
- Registry id
- NCT05047185
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.